In an early-stage clinical trial, scientists used designer immune cells to "reboot" the immune systems of patients with various autoimmune diseases.
The trial used a form of chimeric antigen receptor (CAR) T cell therapy, which has become a mainstay treatment for blood cancers, like leukemia.
